Latest Breaking News On - Sarah cannon research institute - Page 1 : vimarsana.com

Quadruplet Therapy and Early-Line CAR T-Cell Therapy Approvals Mark Shifting Standards in Multiple Myeloma

Minoo Battiwalla, MD, MS, discusses the impact of earlier-line FDA approvals for CAR T-cell therapies on treatment outcomes in multiple myeloma.

United statesMinoo battiwallaAmerican society of hematology annual meetingSarah cannon research institute in nashvilleScience summitSarah cannon research instituteHematology annual

Cancer cases among Gen Xers growing faster compared to previous generations

Gen X patients had decreases in lung and cervical cancer rates, but the rise in other cancers could erase those gains.

United statesDavid spigelSarah cannon research instituteAmerican cancer societyScripps newsAmerican cancer

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

United statesDaiichi sankyoFdad is co burst editionSarah cannon research institute in nashvilleSarah cannon research instituteBurst edition

Osimertinib New Standard of Care for Stage 3, EGFRm NSCLC

Osimertinib New Standard of Care for Stage 3, EGFRm NSCLC
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

United statesSuresh ramalingamSebastian kaulitzkiDavid spigelAmerican society of clinical oncology annual meetingWinship cancer institute of emory universitySarah cannon research instituteAmerican society of clinical oncologyClinical oncologyWinship cancer instituteEmory universityNew england journalProgression free survivalCrossover therapySite briefingClinical oncology annual meeting

Osimertinib delays progression way more than hoped in EGFR -mutant lung cancer

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO

United statesJosh friedmanSureshs ramalingamMindy valcarcelOsimertinib tagrissoJulier gralowDavidr spigelByjosh friedmanWinship cancer institute of emory universitySarah cannon research instituteWinship cancer instituteEmory university